Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190879 | 0.84 | FYN (0.56) | FYNMAPK1KDM1AHDAC1 | |
| SCHEMBL4640360 | 0.78 | CYP1A1 (0.49) | FYNPOLBL3MBTL1BRD4 | |
| SCHEMBL7652997 | 0.76 | KDM4E (0.59) | SMN1; SMN2POLBNPC1 | |
| SCHEMBL4116440 | 0.75 | CYP2C9 (0.55) | KMT2AMEN1MAPTL3MBTL1NPC1 | |
| SCHEMBL30521730 | 0.74 | FYN (1.00) | FYN | |
| SCHEMBL18613388 | 0.74 | FYN (1.00) | FYN | |
| SCHEMBL5418318 | 0.74 | CYP1A2 (0.47) | FYNKMT2ASMN1; SMN2MAPK1LMNA | |
| SCHEMBL12190878 | 0.74 | SMN1; SMN2 (0.63) | KMT2AMEN1MAPTSMN1; SMN2POLB | |
| SCHEMBL12190880 | 0.74 | TAS1R3 (0.55) | KMT2AMEN1MAPTPOLBL3MBTL1 | |
| SCHEMBL12190862 | 0.74 | THRB (0.54) | KMT2AMEN1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | NADK, NAMPT, PDXK | FYN 291/4885KMT2A 1738/4885MEN1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.